Tricuspid regurgitation develops when the tricuspid valve between the right atrium and right ventricle does not close properly. The tricuspid valve controls the blood flow from the right atrium to the ...

PARIS — By assessing residual regurgitation after a transcatheter tricuspid valve repair with a four-grade rather than three-grade system, physicians can predict survival more accurately, reported ...

The FDA approved the Evoque tricuspid valve replacement system as the first transcatheter treatment for tricuspid regurgitation (TR), Edwards Lifesciences announced. Evoque gained an indication for ...

Tricuspid regurgitation — a leak in the heart’s tricuspid valve that allows blood to flow back from the right ventricle to the right atrium — is relatively rare after a mitral valve repair procedure, ...

Moderate/severe tricuspid regurgitation in PAH patients is linked to worse survival, especially with preserved TAPSE or low-risk TAPSE/sPAP ratios. The study emphasizes the prognostic value of ...

The US Food and Drug Administration (FDA) has approved Abbott's TriClip Transcatheter Edge-to-Edge Repair (TEER) system to repair severe tricuspid regurgitation (TR), the company has announced. The ...

Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed. In ...